Coexpression cluster:C182

Full id: C182_renal_mature_mesothelioma_lung_Mammary_Adipocyte_acute

Phase1 CAGE Peaks

Hg19::chr10:26621582..26621588,+	p@chr10:26621582..26621588 +
Hg19::chr10:61530889..61530896,-	p@chr10:61530889..61530896 -
Hg19::chr10:64280228..64280239,+	p11@ZNF365
Hg19::chr11:74751521..74751532,+	p@chr11:74751521..74751532 +
Hg19::chr12:110032559..110032564,+	p@chr12:110032559..110032564 +
Hg19::chr12:110032567..110032577,+	p@chr12:110032567..110032577 +
Hg19::chr12:16109519..16109568,+	p6@DERA
Hg19::chr12:16115719..16115725,+	p8@DERA
Hg19::chr12:49730970..49731010,-	p1@C1QL4
Hg19::chr12:5198337..5198341,+	p@chr12:5198337..5198341 +
Hg19::chr12:5198350..5198359,+	p@chr12:5198350..5198359 +
Hg19::chr12:5198401..5198415,+	p@chr12:5198401..5198415 +
Hg19::chr13:42975929..42975949,+	p@chr13:42975929..42975949 +
Hg19::chr13:49164719..49164734,-	p@chr13:49164719..49164734 -
Hg19::chr14:74296806..74296828,-	p1@ENST00000555539 p1@uc001xov.1
Hg19::chr14:98792210..98792215,-	p@chr14:98792210..98792215 -
Hg19::chr15:67351518..67351557,-	p1@ENST00000558071
Hg19::chr15:67351586..67351591,-	p2@ENST00000558071
Hg19::chr15:85201423..85201439,-	p1@NMB
Hg19::chr16:53780145..53780169,+	p@chr16:53780145..53780169 +
Hg19::chr16:81516526..81516531,+	p@chr16:81516526..81516531 +
Hg19::chr17:38877280..38877286,-	p3@KRT223P
Hg19::chr17:38877316..38877317,-	p4@KRT223P
Hg19::chr18:57877275..57877283,+	p@chr18:57877275..57877283 +
Hg19::chr19:15160130..15160142,+	p3@CASP14
Hg19::chr19:15160255..15160260,+	p4@CASP14
Hg19::chr19:15160267..15160278,+	p2@CASP14
Hg19::chr19:15160280..15160296,+	p1@CASP14
Hg19::chr19:15166954..15166967,+	p@chr19:15166954..15166967 +
Hg19::chr19:15167325..15167344,+	p@chr19:15167325..15167344 +
Hg19::chr19:29492197..29492204,+	p@chr19:29492197..29492204 +
Hg19::chr1:105010925..105010935,-	p@chr1:105010925..105010935 -
Hg19::chr1:115771931..115771941,+	p@chr1:115771931..115771941 +
Hg19::chr1:152140591..152140604,+	p@chr1:152140591..152140604 +
Hg19::chr1:152140624..152140650,+	p@chr1:152140624..152140650 +
Hg19::chr1:152140653..152140680,+	p@chr1:152140653..152140680 +
Hg19::chr1:241790873..241790886,-	p@chr1:241790873..241790886 -
Hg19::chr1:25046836..25046839,+	p@chr1:25046836..25046839 +
Hg19::chr1:25046846..25046851,+	p@chr1:25046846..25046851 +
Hg19::chr1:25046857..25046871,+	p@chr1:25046857..25046871 +
Hg19::chr1:25046892..25046903,+	p@chr1:25046892..25046903 +
Hg19::chr1:69983683..69983707,+	p@chr1:69983683..69983707 +
Hg19::chr20:52784969..52785020,+	p@chr20:52784969..52785020 +
Hg19::chr22:18404843..18404853,-	p@chr22:18404843..18404853 -
Hg19::chr22:30951607..30951613,-	p@chr22:30951607..30951613 -
Hg19::chr22:30951996..30952007,-	p@chr22:30951996..30952007 -
Hg19::chr22:30956754..30956769,-	p2@GAL3ST1
Hg19::chr22:30960863..30960867,-	p12@GAL3ST1
Hg19::chr22:30960879..30960895,-	p1@GAL3ST1
Hg19::chr22:30961419..30961468,-	p10@GAL3ST1
Hg19::chr22:30968796..30968805,-	p11@GAL3ST1
Hg19::chr22:30968813..30968829,-	p9@GAL3ST1
Hg19::chr22:30968839..30968859,-	p6@GAL3ST1
Hg19::chr2:10529417..10529422,+	p@chr2:10529417..10529422 +
Hg19::chr2:120234198..120234212,+	p1@ENST00000457436
Hg19::chr2:166790331..166790338,+	p2@LOC100506134
Hg19::chr2:166790366..166790383,+	p1@LOC100506134
Hg19::chr2:166790396..166790405,+	p1@ENST00000443032 p1@ENST00000446624
Hg19::chr2:58109118..58109152,-	p@chr2:58109118..58109152 -
Hg19::chr2:9519004..9519013,+	p@chr2:9519004..9519013 +
Hg19::chr3:122694165..122694189,-	p7@SEMA5B
Hg19::chr3:122694215..122694221,-	p10@SEMA5B
Hg19::chr3:129375556..129375570,-	p16@TMCC1
Hg19::chr3:187225661..187225665,-	p@chr3:187225661..187225665 -
Hg19::chr4:69915736..69915762,-	p@chr4:69915736..69915762 -
Hg19::chr5:10502761..10502785,-	p2@ENST00000515243
Hg19::chr5:10502793..10502819,-	p1@ENST00000515243
Hg19::chr5:10502847..10502857,-	p3@ENST00000515243
Hg19::chr5:150006500..150006508,-	p@chr5:150006500..150006508 -
Hg19::chr5:31911541..31911549,-	p@chr5:31911541..31911549 -
Hg19::chr5:31995212..31995260,+	p@chr5:31995212..31995260 +
Hg19::chr5:31995297..31995305,+	p@chr5:31995297..31995305 +
Hg19::chr5:31995382..31995392,+	p@chr5:31995382..31995392 +
Hg19::chr5:31995396..31995404,+	p@chr5:31995396..31995404 +
Hg19::chr6:12314642..12314666,+	p@chr6:12314642..12314666 +
Hg19::chr6:154799214..154799219,-	p@chr6:154799214..154799219 -
Hg19::chr6:25868678..25868683,-	p3@SLC17A3
Hg19::chr7:112740700..112740737,+	p1@ENST00000441928
Hg19::chr7:125077880..125077889,+	p4@ENST00000458437
Hg19::chr7:125077895..125077898,+	p5@ENST00000458437
Hg19::chr7:125077915..125077928,+	p1@ENST00000458437
Hg19::chr7:125077931..125077940,+	p3@ENST00000458437
Hg19::chr7:17414360..17414389,+	p1@ENST00000419463
Hg19::chr7:46213508..46213536,+	p@chr7:46213508..46213536 +
Hg19::chr7:46213564..46213575,+	p@chr7:46213564..46213575 +
Hg19::chr7:46213607..46213616,+	p@chr7:46213607..46213616 +
Hg19::chr7:46213930..46213940,+	p@chr7:46213930..46213940 +
Hg19::chr7:46214057..46214073,+	p@chr7:46214057..46214073 +
Hg19::chr7:46214090..46214099,+	p@chr7:46214090..46214099 +
Hg19::chr7:46214112..46214115,+	p@chr7:46214112..46214115 +
Hg19::chr7:57639694..57639702,+	p@chr7:57639694..57639702 +
Hg19::chr8:39542555..39542568,+	p3@ADAM18
Hg19::chrX:144963106..144963110,-	p@chrX:144963106..144963110 -
Hg19::chrY:18943864..18943891,+	p@chrY:18943864..18943891 +

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0000267	cell fraction	0.0154189406315746
GO:0006682	galactosylceramide biosynthetic process	0.0165822834491149
GO:0019375	galactolipid biosynthetic process	0.0165822834491149
GO:0005624	membrane fraction	0.0237674954960085
GO:0046476	glycosylceramide biosynthetic process	0.0237674954960085
GO:0050694	galactose 3-O-sulfotransferase activity	0.0237674954960085
GO:0001733	galactosylceramide sulfotransferase activity	0.0237674954960085
GO:0006681	galactosylceramide metabolic process	0.0237674954960085
GO:0019374	galactolipid metabolic process	0.0237674954960085
GO:0004139	deoxyribose-phosphate aldolase activity	0.0237674954960085
GO:0007283	spermatogenesis	0.0237674954960085
GO:0048232	male gamete generation	0.0237674954960085
GO:0005436	sodium:phosphate symporter activity	0.0248470806030616
GO:0046513	ceramide biosynthetic process	0.0248470806030616
GO:0009264	deoxyribonucleotide catabolic process	0.0248470806030616
GO:0006677	glycosylceramide metabolic process	0.0248470806030616
GO:0007276	gamete generation	0.0248470806030616
GO:0046520	sphingoid biosynthetic process	0.0248470806030616
GO:0007275	multicellular organismal development	0.0280585067008458
GO:0019953	sexual reproduction	0.0310262213524435
GO:0015114	phosphate transmembrane transporter activity	0.0316026226003279
GO:0016832	aldehyde-lyase activity	0.0316026226003279
GO:0009247	glycolipid biosynthetic process	0.0323834920180048
GO:0030148	sphingolipid biosynthetic process	0.0434133450508024
GO:0009166	nucleotide catabolic process	0.0495824162942606
GO:0042552	myelination	0.0495824162942606

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n
epithelial cell	1.71e-20	254
endodermal cell	3.53e-10	59

Uber Anatomy

Ontology term	p-value	n
organ	2.16e-13	511
embryo	1.18e-11	612
epithelium	2.33e-11	309
anatomical conduit	4.24e-11	241
anatomical cluster	6.61e-11	286
cell layer	9.84e-11	312
embryonic structure	1.01e-10	605
developing anatomical structure	1.01e-10	605
trunk region element	1.63e-10	107
germ layer	1.68e-10	604
embryonic tissue	1.68e-10	604
presumptive structure	1.68e-10	604
epiblast (generic)	1.68e-10	604
multi-tissue structure	2.29e-10	347
tube	3.88e-10	194
endoderm-derived structure	1.19e-09	169
endoderm	1.19e-09	169
presumptive endoderm	1.19e-09	169
immaterial anatomical entity	1.85e-09	126
anatomical group	1.85e-09	626
anatomical system	2.12e-09	625
subdivision of trunk	2.27e-09	113
multi-cellular organism	6.57e-09	659
primordium	7.29e-09	168
endo-epithelium	1.76e-08	82
abdomen element	1.81e-08	55
abdominal segment element	1.81e-08	55
digestive system	2.71e-08	155
digestive tract	2.71e-08	155
primitive gut	2.71e-08	155
subdivision of digestive tract	2.89e-08	129
endodermal part of digestive tract	2.89e-08	129
organ part	5.06e-08	219
abdominal segment of trunk	7.55e-08	61
abdomen	7.55e-08	61
exocrine gland	7.64e-08	31
exocrine system	7.64e-08	31
mixed endoderm/mesoderm-derived structure	8.74e-08	130
organism subdivision	1.75e-07	365
gland	2.24e-07	59
foregut	8.58e-07	98

Disease

Ontology term	p-value	n
carcinoma	7.40e-16	106
cell type cancer	3.02e-13	143
adenocarcinoma	3.92e-08	25
disease of cellular proliferation	1.66e-07	239
cancer	2.36e-07	235

Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}

ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

---

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

---

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.